ORIGINAL ARTICLE

Increased treatment requirements of patients with cystic fibrosis who harbour a highly transmissible strain of Pseudomonas aeruginosa

A M Jones¹, M E Dodd¹, C J Doherty², J R W Govan², A K Webb¹

¹ Bradbury Cystic Fibrosis Unit, South Manchester NHS Trust, Wythenshawe Hospital, Manchester M23 9LT, UK
² Department of Medical Microbiology, University of Edinburgh, Edinburgh EH8 9AG, UK

Correspondence to:
Correspondence to:
Dr A M Jones, Adult Cystic Fibrosis Centre, South Manchester NHS Trust, Wythenshawe Hospital, Southmoor Road, Manchester M23 9LT, UK;
andmarkj{at}hotmail.com

Background: A group of patients who harbour the same highly transmissible strain of Pseudomonas aeruginosa were identified at a cystic fibrosis (CF) centre. Isolates of this strain display a number of unusual phenotypic features including resistance to most typical antipseudomonal antibiotics. A study was undertaken to see if there was a difference in treatment requirements between CF patients with chronic infection with their own unique P aeruginosa strains (group 1) and those who harbour a highly transmissible strain (group 2).

Methods: Data on treatment requirements for the year 2000 were collected from the case records of CF patients with chronic P aeruginosa infection who had received inpatient treatment. Patients co-infected with Burkholderia cepacia or other highly transmissible strains of P aeruginosa were excluded.

Results: There were 2/56 and 3/22 deaths in groups 1 and 2, respectively; these patients were excluded from the analysis. No difference was found between the two groups for mean age, % predicted forced expiratory volume in 1 second (FEV₁), % predicted forced vital capacity (FVC), and body mass index. Patients in group 2 had a greater median (range) number of intravenous antibiotic days (60 (17–216) v 33 (4–237) days; p=0.01), inpatient days (39 (7–183) v 16 (1–172) days; p<0.01), and inpatient episodes (3 (1–9) v 2 (1–6); p<0.01), and more respiratory exacerbations (mean (SD) 8.2 (3.4) v 6.1 (3.2); p=0.01).

Conclusions: Patients who harbour the highly transmissible P aeruginosa strain have a greater treatment burden than patients with CF who harbour their own unique strains. These findings support the need for microbiological surveillance for highly transmissible P aeruginosa and the implementation of infection control measures to prevent cross infection.

Keywords: cystic fibrosis; cross infection; Pseudomonas aeruginosa

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Schmid, J., Ling, L. J., Leung, J. L. S., Zhang, N., Kolbe, J., Wesley, A. W., Mills, G. D., Brown, P. J., Jones, D. T., Laing, R. T. R., Pattemore, P. K., Taylor, D. R., Grimwood, K. (2008). Pseudomonas aeruginosa transmission is infrequent in New Zealand cystic fibrosis clinics. Eur Respir J 32: 1583-1590 [Abstract] [Full Text]  
• Conway, S. (2008). Segregation is good for patients with cystic fibrosis. JRSM 101: 31-35 [Full Text]  
• Chambers, D., Scott, F., Bangur, R., Davies, R., Lim, A., Walters, S., Smith, G., Pitt, T., Stableforth, D., Honeybourne, D. (2005). Factors associated with infection by Pseudomonas aeruginosa in adult cystic fibrosis. Eur Respir J 26: 651-656 [Abstract] [Full Text]  
• Lewis, D. A., Jones, A., Parkhill, J., Speert, D. P., Govan, J. R. W., LiPuma, J. J., Lory, S., Webb, A. K., Mahenthiralingam, E. (2005). Identification of DNA Markers for a Transmissible Pseudomonas aeruginosa Cystic Fibrosis Strain. Am. J. Respir. Cell Mol. Bio. 33: 56-64 [Abstract] [Full Text]  
• Griffiths, A. L., Jamsen, K., Carlin, J. B., Grimwood, K., Carzino, R., Robinson, P. J., Massie, J., Armstrong, D. S. (2005). Effects of Segregation on an Epidemic Pseudomonas aeruginosa Strain in a Cystic Fibrosis Clinic. Am. J. Respir. Crit. Care Med. 171: 1020-1025 [Abstract] [Full Text]  
• Van daele, S. G., Franckx, H., Verhelst, R., Schelstraete, P., Haerynck, F., Van Simaey, L., Claeys, G., Vaneechoutte, M., de Baets, F. (2005). Epidemiology of Pseudomonas aeruginosa in a cystic fibrosis rehabilitation centre. Eur Respir J 25: 474-481 [Abstract] [Full Text]  
• Jones, A. M., Dodd, M. E., Govan, J. R. W., Doherty, C. J., Smith, C. M., Isalska, B. J., Webb, A. K. (2005). Prospective Surveillance for Pseudomonas aeruginosa Cross-Infection at a Cystic Fibrosis Center. Am. J. Respir. Crit. Care Med. 171: 257-260 [Abstract] [Full Text]  
• O'Carroll, M.R., Syrmis, M.W., Wainwright, C.E., Greer, R.M., Mitchell, P., Coulter, C., Sloots, T.P., Nissen, M.D., Bell, S.C. (2004). Clonal strains of Pseudomonas aeruginosa in paediatric and adult cystic fibrosis units. Eur Respir J 24: 101-106 [Abstract] [Full Text]  
• Scott, F. W., Pitt, T. L. (2004). Identification and characterization of transmissible Pseudomonas aeruginosa strains in cystic fibrosis patients in England and Wales. J Med Microbiol 53: 609-615 [Abstract] [Full Text]  
• Spilker, T., Coenye, T., Vandamme, P., LiPuma, J. J. (2004). PCR-Based Assay for Differentiation of Pseudomonas aeruginosa from Other Pseudomonas Species Recovered from Cystic Fibrosis Patients. J. Clin. Microbiol. 42: 2074-2079 [Abstract] [Full Text]  
• Al-Aloul, M, Crawley, J, Winstanley, C, Hart, C A, Ledson, M J, Walshaw, M J (2004). Increased morbidity associated with chronic infection by an epidemic Pseudomonas aeruginosa strain in CF patients. Thorax 59: 334-336 [Abstract] [Full Text]  
• Jones, A.M., Martin, L., Bright-Thomas, R.J., Dodd, M.E., McDowell, A, Moffitt, K.L., Elborn, J.S., Webb, A.K. (2003). Inflammatory markers in cystic fibrosis patients with transmissible Pseudomonas aeruginosa. Eur Respir J 22: 503-506 [Abstract] [Full Text]  
• Pitt, T L (2002). Cross infection of cystic fibrosis patients with Pseudomonas aeruginosa. Thorax 57: 921-921 [Full Text]